CD19 and cancer: Lastly, we evaluated 2nd-gen anti-CD19 CAR T cell products generated from four patients either with B-ALL leukemia (PD323, PD356, and PD674) or non-B-ALL cancer (PD145) using our bioengineered chip (Extended Data Fig. 13a,b).